Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol/tetrahydrocannabinol - Axim Biotech

Next Previous
Drug Profile

Cannabidiol/tetrahydrocannabinol - Axim Biotech

Alternative Names: CanChew®Rx; CanChew® RL; CBD/THC gum; MedChew 1401; MedChew 1502; MedChew 1503; MedChew 1504; MedChew GP; MedChew Rx; MedChew-RL; Tetrahydrocannabinol/cannabidiol - Axim Biotech

Latest Information Update: 28 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Axim Biotech
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Dementia; Pain; Parkinson's disease; Postherpetic neuralgia; Psychotic disorders; Restless legs syndrome

Most Recent Events

  • 28 May 2023 No recent reports of development identified for preclinical development in Psychotic-disorders in USA (Buccal)
  • 28 Apr 2021 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in USA (Buccal, Gum)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Dementia in USA (Buccal, Gum)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top